Results 171 to 180 of about 1,597,830 (316)

Systems Engineering Approach to Modeling and Analysis of Chronic Obstructive Pulmonary Disease. [PDF]

ACS Omega, 2023
Kurian V, Ghadipasha N, Gee M, Chalant A, Hamill T, Okossi A, Chen L, Yu B, Ogunnaike BA, Beris AN.   +9 more
europepmc   +1 more source

Interpreting the effects of DNA polymerase variants at the structural level

Molecular Oncology, EarlyView.
Using MAVISp and molecular dynamics simulations, we analyzed over 60 000 missense variants in POLE and POLD1 from ClinVar, COSMIC, cBioPortal, and saturation mutagenesis. Identified mechanistic indicators, including stability, binding, and long‐range, enable structural interpretation, providing ACMG‐like evidence for possible reclassification of VUS ...
Matteo Arnaudi, Karolina Krzesińska, Ludovica Beltrame, Pablo Sánchez‐Izquierdo Besora, Matteo Tiberti, Mef Nilbert, Anna Rohlin, Elena Papaleo   +7 more
wiley   +1 more source

Systems engineering of <i>Escherichia coli</i> for high-level hydroxytyrosol production. [PDF]

Synth Syst Biotechnol
Zuo J, Zhang S, Huang W, Liu J, Gao C, Hu GP, Song W, Li X, Wei W, Wu J, Liu L, Liu K, Xu N.   +12 more
europepmc   +1 more source

Revising human-systems engineering principles for embedded AI applications. [PDF]

Front Neuroergon, 2023
Cummings ML.
europepmc   +1 more source

Proteasome inhibitor, ixazomib prevents topoisomerase‐I degradation and reverses irinotecan resistance in colorectal cancer

Molecular Oncology, EarlyView.
Ixazomib inhibits proteasome‐mediated degradation of topoisomerase I induced by irinotecan, thereby restoring drug sensitivity and promoting tumor cell death in colorectal cancer. Irinotecan, a topoisomerase I (topoI) inhibitor, is widely used for colorectal cancer, but resistance remains a major clinical challenge.
Yuho Ebata, Koji Ando, Hirofumi Hasuda, Koshi Mimori, Elizabeth C. Unan, Siddhartha Pulukuri, Aahana Tiku, Allison Berger, Eiji Oki, Ajit Bharti, Tomoharu Yoshizumi   +10 more
wiley   +1 more source

Process Systems Engineering in Precision Medicine: Opportunities in Autologous CAR-T Therapy. [PDF]

Eng Life Sci
Wayne Bequette B.
europepmc   +1 more source

Metastasis on pause: How dormant tumor cells stay hidden within the tumor microenvironment and evade immune surveillance

Molecular Oncology, EarlyView.
Dormant cancer cells can hide in distant organs for years, evading treatment and the immune system. This review highlights how signals from the surrounding tissue and immune environment keep these cells inactive or trigger their reawakening. Understanding these mechanisms may help develop therapies to eliminate or control dormant cells and prevent ...
Kanishka Tiwary, Jose Javier Bravo‐Cordero   +1 more
wiley   +1 more source

Battery Systems Engineering

, 2013
A complete all-in-one reference on the important interdisciplinary topic of Battery Systems Engineering Focusing on the interdisciplinary area of battery systems engineering, this book provides the background, models, solution techniques, and systems ...
Rahn, Christopher D., Wang, Chao-Yang
core  

A Process Systems Engineering Approach to Model and Optimize Cr⁶⁺-Free and Pd-Free Plating on Plastics Technologies. [PDF]

Polymers (Basel)
Pyrgakis KA, Poupaki E, Kartsinis M, Psycha M, Grigoropoulos A, Zoikis-Karathanasis D, Zoikis-Karathanasis A.   +6 more
europepmc   +1 more source

Circulating tumor cell viability during and after radiotherapy mirrors treatment response in cancer patients

Molecular Oncology, EarlyView.
Radiotherapy (RT) response depends on the DNA repair capacity of tumor and host cells. We show that circulating tumor cell (CTC) counts and apoptosis rates before and after RT predict treatment response and outcome, which can be accessed via easily accessible liquid biopsy approaches. Created in BioRender. Wikman, H.
Yvonne Goy, Jana Löptien, Cornelia Coith, Afroditi Nanou, Katharina Hintelmann, Pinnschmidt Hans, Cordula Petersen, Klaus Pantel, Sabine Riethdorf, Kerstin Borgmann, Harriet Wikman   +10 more
wiley   +1 more source